- Zacks•last month
Genmab (GNMSF) announced that CHMP issued a negative opinion for Arzerra as a maintenance therapy for relapsed chronic lymphatic leukemia.
|52wk Range||501.00 - 1,294.00|
|Day's Range||1,202.00 - 1,226.00|
|Avg Vol (3m)||441,805|
As of 10:59 AM EDT. Market closed.